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[Background]   
Internal pancreatic fistula (IPF) is a well-recognized complication of pancreatic 
diseases. Although there have been many reports concerning IPF, the therapy for IPF 
still remains controversial. We herein report our experiences with endoscopic 
transpapillary pancreatic stent therapy for IPF and evaluate its validity. 
[Method]  
      Six patients with IPF who presented at our department and received endoscopic 
transpapillary pancreatic stent therapy were investigated, focusing on the clinical and 
imaging features as well as treatment strategies, the response to therapy and the 
outcome. 
[Results]  
    All patients were complicated with stenosis or obstruction of the main pancreatic 
duct, and in these cases the pancreatic ductal disruption developed distal to the areas of 
pancreatic stricture. The sites of pancreatic ductal disruption were the pancreatic body 
in five patients and the pancreatic tail in one patient. All patients received endoscopic 
stent placement over the stenosis site of the pancreatic duct, and three patients improved 
completely and one patient improved temporarily. Finally, three patients underwent 
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surgical treatment for IPF. All patients have maintained a good course without 
recurrence of IPF. 
[Conclusion]  
Endoscopic transpapillary pancreatic stent therapy may be an appropriate 
first-line treatment to be considered before surgical treatment. The point of stenting for 
IPF is to place a stent over the stenosis site of the pancreatic duct to reduce the 
pancreatic ductal pressure and the pseudocyst’s pressure. 
 
 
Key words: internal pancreatic fistula, endoscopic transpapillary pancreatic stent, 












       Internal pancreatic fistula (IPF) is a rare clinical entity, but it is a well-known 
serious complication of acute and chronic pancreatitis or pancreatic trauma 1-3) and is 
associated with significant morbidity and mortality 3-6). IPF is caused by the disruption 
of the pancreatic duct due to the associated disease. An inflammation or traumatic 
disruption of the pancreatic duct leads to the leakage of pancreatic exocrine secretions. 
If the duct is disrupted anteriorly, the disruption leads to pancreatic ascites. If the duct is 
disrupted posteriorly, the disruption may lead to the tracking of pancreatic fluid into the 
mediastinum along the path of least resistance through the aortic and esophageal hiatus, 
thus resulting in mediastinal pseudocyst or pleural fistula with amylase-rich pleural 
effusion 3, 7-11).  
       The traditional treatments for IPF include conservative medical therapy or 
surgery. However, these treatments have had limited success 6, 12, 13). The conservative 
therapy fails in approximately half the cases while surgical treatment is associated with 
significant morbidity 14). Although endoscopic transpapillary pancreatic stent therapy 
for IPF has been reported to be useful as an alternative treatment modality, the treatment 
strategy for IPF remains controversial. We herein report our experience with endoscopic 
transpapillary pancreatic stent therapy for IPF and evaluate its validity. 




Treatment strategy for IPF in our department 
       Figure 1 shows a schema of the treatment strategy for IPF in our department. 
After IPF was identified using various modalities such as ultrasonography (US), helical 
computed tomography (CT), and MR-cholangiopancreatography (MRCP), the 
pancreatic ductal system was investigated in detail in all cases using endoscopic 
retrograde cholangiopancreatography (ERCP). At the same time as ERCP, endoscopic 
transpapillary pancreatic stent placement was performed over the stenosis site of the 
pancreatic duct and endoscopic sphincterotomy was not performed at same time. Figure 
2 shows the schema of endoscopic transpapillary pancreatic stent placement of our 
treatment strategy for IPF. The size of the stent was selected to be either 5 or 7 Fr (Cook 
Endoscopy, Winston, USA). Although the 7Fr stent was tried to place at first, the 5Fr 
stent was adapted to the cases which were difficult for the 7Fr stent to place. The 
exchange interval for the stent was set to be every four months, and the total placement 
period of the stent was one year. When a symptom worsened or stenting was not 
effective, surgical procedures were considered. 
Patients 
     Six patients with IPF who presented in the Department of Surgery at Nagasaki 
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University Hospital between July 2007 and November 2011 were included in this study. 
The clinical and imaging records were reviewed and compared among the patients. 
Imaging studies included US, CT, MRCP, and ERCP. In addition, parameters related to 
the treatment for IPF such as the stent size, interval for stenting, response to therapy, 


















       The clinical features of six patients with IPF are summarized in Table 1. All 
patients were men with a mean age of 64 years (range, 58 to 71 years). Five patients 
showed pancreatic ascites and one patient showed a mediastinal pseudocyst. As the 
main symptoms, three patients showed back pain, two patients showed abdominal pain, 
and one patient showed epigastralgia and abdominal distension. The underlying disease 
associated with IPF included alcohol-related chronic pancreatitis in all patients. The  
serum amylase and C-reactive protein (CRP) levels were 238±401 (IU/l) and 7.9±9.9 
(mg/dl), respectively. The white blood cell count was 10,900±3,482 (/mm3). The fluid 
amylase level within ascites or pseudocysts was 46,890±2,2921 (IU/l). Four patients 
presented IPF after the acute aggravation of chronic pancreatitis. 
       Table 2 shows the imaging features of the patients. All patients received US, 
enhanced-CT, MRCP and ERCP. According to these modalities, the sites of pancreatic 
ductal disruption were the pancreatic body in five patients and the pancreatic tail in one 
patient. All patients were complicated with stenosis or obstruction of the main 
pancreatic duct and the pancreatic ductal disruption developed distal to the areas of the 
pancreatic structure. Four patients were complicated with pancreatic calculi; these were 
located in the whole pancreas in two patients, the head and body of pancreas in one 
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patient and only the head of pancreas in one patient. Five patients were complicated 
with pancreatic pseudocysts. Two patients were complicated with retroperitoneal 
abscesses. 
       Table 3 shows the results of endoscopic transpapillary pancreatic stent therapy 
for IPF. All patients received endoscopic transpapillary stent therapy according to our 
treatment strategy for IPF and the success rate of stent placement was 100%. Three 
patients became asymptomatic by stenting for IPF and did not have a recurrence after 
the stent was withdrawn. Figure 3 shows a successful case of endoscopic transpapillary 
pancreatic stent therapy for IPF; the pancreatic effusion disappeared after the stent 
therapy. Although two patients received the stent therapy, Case 4 continued to suffer 
from continuous pain and Case 5 was complicated with intracystic bleeding. Case 6 had 
become asymptomatic through stenting therapy and had been free of continuous pain 
for 13 months after the stent was removed. However, the symptoms recurred, and the 
replacement of the stent was not effective enough to improve the symptoms in Case 6. 
Finally, Case 4, 5, and 6 underwent surgical treatment and became asymptomatic 
afterwards. All patients have maintained a good course without the recurrence of IPF for 
a mean observation period of 3.2 years (range 1.1 years to 5.4 years). 
 




       IPF is rare clinical entity and Chebli et al reported that the incidence has been 
11 patients (7.3%) of 150 patients with chronic pancreatitis from 1995 to 2003 15). 
Because of the low incidence, the treatment strategy for IPF remains controversial. 
However, endoscopic transpapillary pancreatic stent therapy for IPF has been reported 
to be useful as an alternative treatment modality. Our treatment strategy for IPF was 
used in all patients, and the validity of our strategy was evaluated. Furthermore, the 
important point of this study was to treat the patients with IPF using endoscopic stenting 
according to our original strategy. In this study, all patients had received endoscopic 
transpapillary pancreatic stent therapy during ERCP, and three patients showed 
complete improvement without recurrence. On the other hand, three patients finally 
required surgical intervention. We directed the operative procedures to control 
intracystic bleeding and to relieve continuous pain, thus resulting in favorable 
outcomes. 
       IPF with pancreatic ascites and pleural effusion shares a common 
pathophysiology. The disruption of the pancreatic duct results in the formation of 
internal fistula communicating with peritoneal or pleural cavities, which result in ascites 
or pleural effusion, respectively 5, 16). In most cases, IPF has been reported to develop 
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secondary to alcoholic chronic pancreatitis 17-21). In the present study, all patients 
presented pancreatic ascites or pleural effusion. Moreover, in all patients IPF developed 
secondary to alcoholic chronic pancreatitis and four patients presented with IPF after an  
acute aggravation of chronic pancreatitis.  
   The diagnosis of IPF generally relies on imaging. Some reports have shown that 
the diagnostic sensitivity of MRCP is almost the same as that of ERCP and is higher 
than that of CT 21-23). Our previous report found that a precise assessment of the 
pancreatic ductal system is essential for effectively managing patients with IPF; MRCP 
can be a promising tool for evaluating the pancreatic duct system, and it is also helpful 
for selecting the optimal treatment strategy 24). The previous reports showed that ERCP 
is the most specific modality for identifying the pancreatic duct anatomy and the site of 
disruption. The reported advantage of ERCP is that it offers the opportunity for 
definitive therapy using an endoscopic stent, sphincterotomy, or nasopancreatic 
drainage  25, 26).  
      The available treatment modalities for IPF are 1) conservative medical therapy, 
2) surgery, and 3) endoscopic transpapillary pancreatic stent therapy. The aim of 
medical therapy is to reduce pancreatic exocrine secretions 27). However, several reports 
have shown that the therapeutic rates of somatostatin or octreotide and parecentesis 
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were 25-60% lower3, 4, 6, 12, 13). Moreover, medical therapy is expensive and, requires 
prolonged hospitalization, and failure to respond for more than four weeks is associated 
with mortality rates ranging from 1-25% 5, 13). In this study, medical therapy such as 
somatostatin or octreotide was not used for any cases. On the other hand, the main 
indications for surgery are the failure of other treatments, obstruction of the pancreatic 
duct, intracystic bleeding, and cases in which symptoms did not improve. Surgical 
treatment includes either some form of pancreatic resection or enter-pancreatic 
anastomosis at the site of pancreatic duct leakage or the pseudocyst 28). However, 
surgical treatment has the disadvantages of the potential for complications and the 
occurrence of death in 1-20% 4, 5, 17). Whereas, the aim of endoscopic transpapillary 
pancreatic stent therapy is to reduce the main pancreatic ductal pressure and the 
pseudocyst’s pressure 29-31). Complications of endoscopic stenting include perforation, 
bleeding, exacerbation of pain due to acute pancreatitis, infection of associated fluid 
collections, alterations in ductal morphology following stenting and death. Adverse 
events have been reported in 0-9% 32). The most important objective of stent therapy is 
to place the stent over the stenosis site of the pancreatic duct. Our previous report also 
found that a sufficient decompression of pancreatic stricture is mandatory for the 
treatment of patients with IPF 24). Therefore, there is also the report that combined 
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endoscopic and percutaneous rendezvous technique is the efficient method to reduce the 
pressure in cases of failure of endoscopic stenting 33). Although stent therapy has been 
reported to be more invasive and carries a greater risk than medical therapy, it has been 
reported to be safer than surgical treatment 25, 26).  
In conclusion, it may be useful to consider endoscopic stent therapy before 
surgical treatment. Because the cause of IPF is stenosis of the pancreatic duct, it is 
important to remove this stenosis in order to resolve the condition. However, since there 
were few cases in this study, it is required to accumulate and examine IPF cases, 
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Figure Legends 
Figure 1: Treatment strategy for IPF in our department 
After IPF was identified using various modalities such as US, enhanced-CT, and MRCP, 
in all cases the pancreatic ductal system was investigated in detail using ERCP. At the 
same time as ERCP, endoscopic transpapillary pancreatic stent placement was 
performed over the stenosis site of the pancreatic duct. The size of the stent was selected 
to be either 5 or 7 Fr (Cook Endoscopy, Winston, USA). The exchange interval for the 
stent was set to be every four months, and the total placement period of the stent was 
one year. When a symptom worsened or stenting was not effective, surgical procedures 
were considered. 
Figure2: Schema of endoscopic transpapillary pancreatic stent placement  
In order to reduce the main pancreatic ductal pressure and the pseudocyst’s pressure, it 
is important to place the stent over the stenosis site. 
Figure 3: A case of endoscopic transpapillary pancreatic stent therapy 
The stent was placed over the site of the stenosis (white arrow). 
Figure 1 Treatment strategy for IPF in our department  
Identification of IPF using modalities (US, CT, MRCP) 
Placement of stent (5Fr or 7Fr) using ERCP 
Surgery Exchange interval of the stent: every four months  
Total period of placement of the stent: one year. 
No recurrence Recurrence 
Unsuccessful Successful 
Follow up 
removal of stent 
retry 
Figure 2. Schema of endoscopic transpapillary pancreatic stenting  
Placement of stent over the stenosis 





Figure 3. A case of endoscopic transpapillary pancreatic stenting  
Table 1. Clinical feature of six patients with IPF 















case1 58 Male PA CP Alcohol Back pain 257 7.8 1.2 17,684 
case 2 61 Male PA CP Alcohol Abdominal pain 219 12.8 26.3 64,090 
case 3 70 Male PA CP Alcohol Back pain 1,143 12.6 11.7 82,980 
case 4 64 Male PA CP Alcohol Abdominal pain 21 16.0 20.4 - 
case 5 71 Male MP CP Alcohol Epigastralgia Back pain 689 9.2 4.1 32,890 
case 6 62 Male PA  CP Alcohol 
Abdominal 
distension 35 5.6 0.1 46,890 
PA: pancreatic ascites, MP: mediastinal pseudocyst, CP: chronic pancreatitis, WBC: white blood cell count, CRP: C-reactive protein 
Table 2. Imaging feature of six patients with IPF 









case1 ○ ○ ○ ○ Body + (Head) - + - 








case 4 ○ ○ ○ ○ Body + (Body) + (Head-Tail) + - 
case 5 ○ ○ ○ ○ Body + (Body) + (Head-Body) + - 
case 6 ○ ○ ○ ○ Body + (Body) + (Head) - - 
















case1 + 5Fr 1 year Well - + 2.3 year - 
case 2 + 7 Fr 1 year Well - + 2.2 year - 
case 3 + 7Fr 1year Well - + 5.4 year  - 
case 4 - 5Fr 2 months Continuous pain  
Partington’s 
procedure + 1.6 year - 
case 5 + 5Fr 1.5 months Intracystic bleeding 
Distal 
pancreatectomy + 1.1 year - 
case 6 + 5Fr 1 year Well - + 3.4 year 
+ 
Continuous pain recurred 
at13months after the 
removal of the stent. In 
spite of the replacement of 
the stent, symptoms did not 
improve. 
             →Frey’ procedure 
*Response for treatment means that symptoms, pancreatic stenosis, or amount of effusion disappear.  
